RESULTS: All 38 patients (100%) attained DU criteria for successful AVF maturation after 14 days of creation. 81% of patients had successful AVF puncture after 14 days, 5% patients after 8 days, while 13% after 6 months of creation, as they did not require urgent dialysis. Significant difference was observed between 1st and 14th day in ARd (2,06 vs 3,71mm, p¼0.001) and CVd (2,62 vs 5,33, p¼0.001). Preoperative mean values of measured parameters were: VD 0,5560,20mm (0,2-0,9), RI 0,8260,07 (0,95) while postoperative were: AVF area (anastomosis) 3,8560,93mm (2,2-5,9) and AVF flow 1001,186520,26 (440-2500) We aimed to evaluate the association between the degree of AVF stenosis and neutrophil activation status by measuring circulating levels of elastase and lactoferrin. Also, we tried to find out the role of angiogenin, which was known as neutrophil degranulation inhibitory protein, in the degree of AVF stenosis.
INTRODUCTION AND AIMS:
Although arteriovenous fistula (AVF) dysfunction is a major cause of hospitalization and morbidity in hemodialysis (HD) patients, detailed pathogenesis of AVF complications such as stenosis and thrombosis is still under investigation. Leukocytes have been shown to play an important role in the development AVF stenosis. Nevertheless, prior reports have focused on cells on monocyte lineage, and little is known about the possible role of neutrophils. We aimed to evaluate the association between the degree of AVF stenosis and neutrophil activation status by measuring circulating levels of elastase and lactoferrin. Also, we tried to find out the role of angiogenin, which was known as neutrophil degranulation inhibitory protein, in the degree of AVF stenosis. METHODS: We examined circulating levels of elastase, lactoferrin and angiogenin as well as other clinical and biochemical parameters in 54 patients who received HD with native AVF for more than 3 months. Degree of AVF stenosis was expressed by the percent of the greatest stenotic diameter to the widest adjacent vessel diameter by ultrasound. RESULTS: Circulating elastase and lactoferrin levels were strongly correlated with each other (r¼0.809, p¼0.000). The degree of AVF stenosis was positively correlated with elastase (r¼0.278, p¼0.042) and lactoferrin (r¼0.282, p¼0.039) levels. However there was no significant correlation between the degree of AVF stenosis and angiogenin level. Patients with severe AVF stenosis (stenosis > 50%) were older (67.968.3 vs 57.2614.3 yrs, p¼0.007), had longer dialysis vintage (7.064.0 vs 4.364.0 yrs, p¼0.027), duration of AVF use (6.964.0 vs 3.863.5 yrs, p¼0.008), and higher elastase (414.96294.5 vs 228.06154.5 ng/ml, p¼0.027), lactoferrin (11.966.5 vs 6.263.0 ng/ml, p¼0.004) levels compared with the other group. There was no significant difference in gender, presence of diabetes, angiogenin levels, and other biochemical measurements including hsCRP, calcium, phosphorus, iPTH, cholesterol according to the degree of AVF stenosis. In multivariable analysis, however, only age and duration of AVF use were significant independent predictors for the degree of AVF stenosis. CONCLUSIONS: Circulating levels of lactoferrin and elastase, indirect markers of neurophil activation, were closely associated with the degree of AVF stenosis. Larger scale studies are needed to show whether they could be used as independent predictors of atrisk AVF stenosis. 
FP569 PRELIMINARY RESULTS OF A FIRST CLINICAL STUDY WITH A NOVEL BONE ANCHORED VASCULAR ACCESS DEVICE

INTRODUCTION AND AIMS:
Conventional central venous dialysis catheters are prone to infections. Studies on bone anchored devices fixed to the mastoid, such as bone anchored hearing aids on the other hand have reported only minimal infection rates. We hypothesize that a central venous dialysis catheter that ends in a transdermal port fixed to the region of the mastoid might result in a lower infection rate. METHODS: We have previously reported not only on the design of such a bone anchored port, but on all the necessary techniques, tools and templates designed for a successful surgical implantation. Furthermore, we have created a tool to derive a map of bone thickness based on a preoperative petrous bone CT scan to determine the best location for the bone anchored port. RESULTS: The novel dialysis vascular access port has so far been implanted into four patients. The surgical implantation of these devices went without complications. In two patients we observed a delayed healing of the cutaneous wound around the port that required surgical revision in one diabetic patient. The port can theoretically be used immediately after implantation for dialysis. In our patients it was used on average 9 (2 to 15) days after implantation. The inner valve of the first implanted BAP was leaky. This part is replaceable without surgical intervention. Replacement of the faulty part lead to a slight design modification. The current observation period is 24 patient months (2 to 14 month). All patients are treated without problems at their prescribed blood flow of 300 ml/min. So far no catheter related infections have been observed. CONCLUSIONS: We conclude that these first results look promising and we will continue recruiting patients for this ongoing study.
FP570 VASCULAR ACCESS OUTCOMES IN INTENSIVE HEMODIALYSIS PATIENTS -A CHANGING PARADIGM?
Kelia Xavier INTRODUCTION AND AIMS: Native arteriovenous fistula (AVF) is regarded as the best access for hemodialysis (HD). Patients accepted for dialysis are increasingly elderly and with comorbidities, in whom creation of an AVF may be neither possible nor appropriate. Frequent HD is possibly associated with an increased risk of vascular access complications. Central venous catheter is considered an inferior vascular access option to conventional thrice-weekly HD, but there have been no studies comparing different vascular access types in a frequent hemodialysis setting. This study aims to determine frequency and outcomes of AVF and tunneled hemodialysis catheter (THC) on incident in-center short daily hemodialysis (SDHD) patients over a 12-year period. METHODS: Data were collected on the type of access used for first HD, including AVF, THC, temporary central venous catheter (tCVC) or arteriovenous graft (AVG) from January 2006 to December 2017. Comparative outcomes between AVF and THC were analyzed, such as absence of access dysfunction, access-related infection and access-related hospitalizatIon. Informations were also gathered on cumulative transplantation rate and 5-year actuarial survival of 117 consecutive unselected private-insured patients (63M/54F; mean age at dialysis initiation was 57.8620.7 yrs, range 8-92) receiving in-center short daily hemodialysis treatments (6-7 times/week; lasting 118618.7 min, range 90-180; ultrapure dialysate and single-use highflux dialyzer). All vascular procedures were done by an associated vascular surgeon with extensive experience in determining eligibility for hemodialysis access type and location, as well as placement and follow up care. Buttonhole cannulation was the standard technique for AVF punctures, while THC use protocol included dedicated nursing team, transparent dressing, closed connector device and use of antibiotic lock and thrombolytic drugs whenever needed. RESULTS: A total of 117 incident short daily hemodialysis patients were enrolled in the study. Thirty-three percent (39/117) were first dialyzed through a mature arteriovenous fistula (AVF), while 67% (78/117) required an internal jugular catheter for starting HD -40% THC and 27% tCVC. Throughout follow-up 71% (22/31) of tCVC switched to THC, while 29% (9/31) converted to AVF (p¼0.001). No patients used AVG. There was a trend of THC users at dialysis initiation to be older (63.8622.9 vs 55.4618.1 yrs, p¼0.069), diabetic (38% vs 28%, p¼0.334) and less likely to get transplanted (15% vs 32% cumulative kidney transplantation rate, p¼0.064), whilst having a significantly lower cumulative 5-year survival (45% vs 74%, p¼0.007) when compared to AVF users. Over the 12-year study period 53% of AVF and 47% of THC needed no repair, replacement or modality shift (p¼0.585). Access local or exit site infection rates were 0.49 and 1.04 events per 1,000 patients-and catheter-days in AVF and THC users (p¼0.772) and bacteremia rates were 0.27 and 0.47 events per 1,000 patients-and catheter-days, respectively (p¼0.881). Access-related medical hospitalization occurred only once in a THC user (endocarditis). CONCLUSIONS: In our in-center short daily hemodialysis program using the vascular access up to twice as often, in spite of adverse inherent patient characteristics starting hemodialysis with THC, under strict placement and maintenance protocols, has provided long-term access outcomes similar to AVF. Vascular access may no longer be a barrier for enhancing adoption of intensive hemodialysis. 
